Biologics To Post Record Results
Wednesday, 02 June 2010 11:03 AM
Montreal, Canada and Irvine, CA, USA. Monday, June 2, 2010
Viropro is pleased to report that its 100% owned subsidiary, Biologics Process Development, Inc. (“BPD”) of Poway/San Diego, CA will post its best ever financial results.
Scott M. Brown, Ph. D. and founder of BPD comments: “This is a proud achievement for our team. BPD has through the years built a solid reputation in the fields of molecular biology, recombinant protein expression & purification, cell culture and microbial fermentation, frozen cell/material storage, and consulting services in biologics process development. I attribute our strong growth not only to hard work and perseverance but also to the recognition of our expertise and to the development of our network of service providers.”
Rajiv Datar, Ph.D., on behalf of Viropro, adds: “From the onset of the new Business Plan adopted in August of last year, it was our priority to reflect increased revenues in Viropro. Our IP and technological knowhow in biopharmaceuticals development have led us, and will continue to lead us, toward long-term contractual agreements with current and future clients. Recently initiated discussions with one of our partner companies, Intas Biopharmaceuticals Ltd. of India, provide access to complementary services and facilities to execute global contractual research and production agreements. Building on these cornerstones will bring added value to our shareholders.”
Audited financial statements of BPD will be posted on Edgar by the end of the second quarter of 2010 and will be consolidated accordingly with Viropro’s financial results for the same period.
About Viropro, Inc.:
Viropro Inc. conducts operations through its subsidiaries Viropro International Inc., and Biologics Process Development, Inc. and specializes in the transfer of its technologies for industrial production of biopharmaceutical therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. The Company’s principal objective is to provide its high-yield manufacturing process technology to biopharmaceutical companies in global markets with unmet medical and/or market needs. (www.viropro.com)
About Biologics Process Development, Inc.:
Biologics Process Development, Inc. (BPD), located in Poway (San Diego area), California, has been providing contract laboratory services to the biotechnology and biopharmaceutical industries for fourteen years. The range of services includes molecular biology, cell culture, fermentation, protein purification, frozen storage, process scale-up and consulting services. BPD has an impressive list of clients that range from university laboratories to well-known biotechnology and biopharmaceutical companies. (www.biologicspd.com)
About Intas Biopharmaceuticals Limited:
Intas Biopharmaceuticals Limited is a fully integrated biopharmaceutical company based out of Ahmedabad, Gujarat, India. Since launch of biotechnology operations in May 2000, Research & Development (R&D) and Manufacturing of Biopharmaceutical Products with a special focus on oncology (cancer) are the major thrust areas for the company. Intas Biopharmaceuticals is India's first and only biopharmaceutical company to receive European Union-Good Manufacturing Practice (EU-GMP) certification for its manufacturing facility. (www.intasbiopharma.co.in)
Viropro Inc. Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.
For more information on Viropro Inc., please visit our website on www.viropro.com
Viropro:
(514) 465 2722
